Efficacy/Safety Study to Confirm Iberogast's Efficacy in Patients With Irritable Bowel Syndrome Diagnosed on ROME III Criteria Compared to Placebo

NCT01940848 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Irritable Bowel Syndrome

Interventions

DRUG: STW5 (Iberogast, BAY98-7411)
DRUG: Placebo

Sponsor

Bayer